Evidence map›Paper›PMID 36112662›Full record

ArticlePLoS genetics2022

Testing for association with rare variants in the coding and non-coding genome: RAVA-FIRST, a new approach based on CADD deleteriousness score.

Ozvan Bocher, Thomas E Ludwig, Marie-Sophie Oglobinsky, Gaëlle Marenne, Jean-François Deleuze, Suryakant Suryakant, Jacob Odeberg, Pierre-Emmanuel Morange, David-Alexandre Trégouët, Hervé Perdry and 1 more

Abstract read
In one paragraph

Article in PLoS genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ozvan BocherUniv Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.ORCID 0000-0002-2467-9236
Thomas E LudwigUniv Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.ORCID 0000-0002-9996-1084
Marie-Sophie OglobinskyUniv Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.
Gaëlle MarenneUniv Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.ORCID 0000-0002-4363-7170
Jean-François DeleuzeCentre National de Recherche en Génomique Humaine CNRGH, Institut de Biologie François Jacob, Université Paris Saclay, CEA, Evry, France.
Suryakant SuryakantUniversity of Bordeaux, Inserm, Bordeaux Population Health Research Center, team ELEANOR, UMR 1219, Bordeaux, France.
Jacob OdebergScience for Life Laboratory, Department of Protein Science, CBH, KTH Royal Institute of Technology, Stockholm, Sweden.ORCID 0000-0003-0996-1644
Pierre-Emmanuel MorangeAix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.ORCID 0000-0002-9065-722X
David-Alexandre TrégouëtUniversity of Bordeaux, Inserm, Bordeaux Population Health Research Center, team ELEANOR, UMR 1219, Bordeaux, France.ORCID 0000-0001-9084-7800
Hervé PerdryCESP Inserm, U1018, UFR Médecine, Univ Paris-Sud, Université Paris-Saclay, Villejuif, France.ORCID 0000-0001-7570-1678
Emmanuelle GéninUniv Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.ORCID 0000-0003-4117-2813

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare variant association tests (RVAT) have been developed to study the contribution of rare variants widely accessible through high-throughput sequencing technologies. RVAT require to aggregate rare variants in testing units and to filter variants to retain only the most likely causal ones. In the exome, genes are natural testing units and variants are usually filtered based on their functional consequences. However, when dealing with whole-genome sequence (WGS) data, both steps are challenging. No natural biological unit is available for aggregating rare variants. Sliding windows procedures have been proposed to circumvent this difficulty, however they are blind to biological information and result in a large number of tests. We propose a new strategy to perform RVAT on WGS data: "RAVA-FIRST" (RAre Variant Association using Functionally-InfoRmed STeps) comprising three steps. (1) New testing units are defined genome-wide based on functionally-adjusted Combined Annotation Dependent Depletion (CADD) scores of variants observed in the gnomAD populations, which are referred to as "CADD regions". (2) A region-dependent filtering of rare variants is applied in each CADD region. (3) A functionally-informed burden test is performed with sub-scores computed for each genomic category within each CADD region. Both on simulations and real data, RAVA-FIRST was found to outperform other WGS-based RVAT. Applied to a WGS dataset of venous thromboembolism patients, we identified an intergenic region on chromosome 18 enriched for rare variants in early-onset patients. This region that was missed by standard sliding windows procedures is included in a TAD region that contains a strong candidate gene. RAVA-FIRST enables new investigations of rare non-coding variants in complex diseases, facilitated by its implementation in the R package Ravages.

Indexed as

Genetic VariationGenomicsDNA, IntergenicExomeHigh-Throughput Nucleotide SequencingHumansDNA, Intergenic

Identifiers

PMID36112662
PMCPMC9518893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.